Track Hikal Ltd.'s current share price, historical price chart, 52-week high/low, and performance across different time periods.
1 Week returns: -0.43 %
Low
210.7
High
219.9
1 Month returns: -2.53 %
Low
210.7
High
239.9
1 Year returns: -16.90 %
Low
145.9
High
282.7
3 Year CAGR: -9.84 %
Low
145.9
High
464.8
5 Year CAGR: -19.36 %
Low
145.9
High
729.0
Note: Prices may be delayed by a few minutes. For historical calculations, prices are adjusted for splits, bonus and rights issue. Percentage change shown is absolute irrespective of the period.
Multi-year trends for Hikal Ltd. covering revenue, net profit, ROE, and EBITDA for a quick view of financial health over time.
Hikal Ltd. Shareholding Pattern
Quarterly breakdown of Hikal Ltd. ownership including promoter, FII, DII, mutual fund, and public holdings as disclosed to NSE/BSE.
Bulk, Block and Insider Trades
Recent bulk deals, block deals, and insider trading activity in Hikal Ltd. shares as reported to NSE and BSE.
Frequently Asked Questions
What is the current share price of Hikal Ltd.?
The current share price of Hikal Ltd. is ₹ 211.90 as of 24 Aug 2026.
What is the market capitalisation of Hikal Ltd.?
The market capitalisation of Hikal Ltd. stands at ₹ 2,658.49 Cr.
What is the PE ratio of Hikal Ltd.?
The Price-to-Earnings (PE) ratio of Hikal Ltd. is - as of the latest trailing twelve months data.
What is the ROE and ROCE of Hikal Ltd.?
Hikal Ltd. has a Return on Equity (ROE) of -3.97% and a Return on Capital Employed (ROCE) of 2.90% as per the latest financial reports.
What is the 52-week high and low of Hikal Ltd.?
The 52-week high of Hikal Ltd. is - and the 52-week low is -.
What is the dividend yield of Hikal Ltd.?
The dividend yield of Hikal Ltd. is 0.28% based on the current market price.
What is the FII and DII holding in Hikal Ltd.?
Foreign Institutional Investors (FII) hold 0.98%, Domestic Institutional Investors (DII) hold 5.92% and retail/public investors hold 21.67% of Hikal Ltd. shares.
What sector does Hikal Ltd. belong to?
Hikal Ltd. operates in the Healthcare sector.
What is the beta of Hikal Ltd.?
The beta of Hikal Ltd. is 1.52, indicating its price volatility relative to the broader market. Over the past 1 year, Hikal Ltd. has delivered an absolute return of -15.66%.
What is the RSI of Hikal Ltd.?
The 14-day Relative Strength Index (RSI) of Hikal Ltd. is 47.01, placing it in the neutral zone. An RSI above 70 is considered overbought and below 30 is considered oversold.
Stock Analysis
Fundamental analysis overview of Hikal Ltd. covering key investment insights, growth drivers, risk factors, and potential red flags.
Views
Red Flags
Positive
Low Debt to Equity, not much change from last year
The company has low Debt to Equity of 0.57 as on 30 Jun 2026 and Debt to Equity decreased marginally by 0.04 in the last 1 year
What is Debt to Equity?
Consistently pays dividend
The company has not missed dividend payments once in the last 10 financial years
What is Dividend streak?
Negative
Stock is fairly expensive with negative EPS on a trailing 12-month basis
Earnings yield of -1.61% indicates that the stock is very expensive and has a negative EPS on a trailing 12-month basis
What is Earnings yield (E/P)?
Low and declining ROE
The company reported low ROE of -3.97% for 12-month ended 30 Jun 2026 and ROE declined by -1138 bps from 1 year ago
What is ROE (FY)?
Low and declining operating margin
The company reported low operating margin of 3.3% for 12-month ended 30 Jun 2026 and operating margin declined by -507 bps from 1 year ago
What is Operating profit margin?
Low revenue growth and lower than median growth of industry
The company delivered moderate revenue growth of -5.37% for 12-month ended 30 Jun 2026 and the growth was 15.96 percentage points lower than median growth of industry
What is Sales growth (1Y)?
Median: 10.59
Value -5.37
-99.6111701.8
Low EPS growth and lower than median growth of industry
The company delivered moderate EPS growth of -153.39% for 12-month ended 30 Jun 2026 and the growth was 160.59 percentage points lower than median growth of industry
What is EPS growth (1Y)?
Low dividend yield
The company has a low dividend yield of 0.28%
What is Dividend yield?
Neutral
Company's earnings are of moderate quality
Earnings quality score of 58.8 indicates that the company's earnings are of moderate quality. Earnings quality is measured using combination of earnings persistence, probability of manipulation and earnings to cash conversion
What is Earnings quality score?
58.8 / 100
No red flags found!
No significant red flags found in the stock.
Net Revenue FY
Profit After Tax FY
ROE FY
EBITDA FY
Mar 2020
Jun 2020
Sep 2020
Dec 2020
Mar 2021
Jun 2021
Sep 2021
Dec 2021
Mar 2022
Jun 2022
Sep 2022
Dec 2022
Mar 2023
Jun 2023
Sep 2023
Dec 2023
Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Total Promoter
68.77
68.77
68.77
68.77
68.77
68.77
68.77
68.77
68.77
68.77
68.77
68.83
68.85
68.85
68.85
68.85
68.85
68.85
68.85
68.85
68.85
68.85
68.85
68.85
68.85
68.85
Indian Promoter
68.77
68.77
68.77
68.77
68.77
68.77
68.77
68.77
68.77
68.77
68.77
68.83
68.85
68.85
68.85
68.85
68.85
68.85
68.85
68.85
68.85
68.85
68.85
68.85
68.85
68.85
Foreign Promoter
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Institutions
7.11
7.80
6.47
5.59
6.50
4.90
6.95
7.30
7.81
4.80
5.64
5.97
6.74
7.34
7.93
9.28
10.08
9.84
10.36
9.54
9.49
9.38
9.39
9.36
8.63
8.23
Mutual Funds / UTI
1.07
1.26
1.01
0.51
0.45
0.49
0.38
0.23
0.76
0.77
1.10
1.30
1.79
2.39
2.72
2.71
3.03
2.73
3.22
2.92
2.93
2.97
4.09
5.71
5.92
5.92
FI/Bank/Insurance
1.07
1.03
0.86
0.12
0.12
0.12
0.12
0.12
0.12
0.12
0.12
0.12
0.12
0.12
0.12
0.12
0.12
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Govt
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
FII
4.86
5.41
4.55
4.91
5.91
4.20
6.36
6.91
6.92
3.91
4.27
4.40
4.56
4.56
4.81
6.14
6.55
6.66
6.78
6.06
5.70
5.35
4.23
2.31
1.44
0.98
Other Institutions
0.10
0.10
0.05
0.05
0.02
0.09
0.09
0.03
0.00
0.00
0.15
0.15
0.27
0.27
0.27
0.32
0.38
0.44
0.36
0.56
0.87
1.06
1.06
1.34
1.28
1.31
Non-Institution
24.12
23.43
24.76
25.64
24.73
26.33
24.28
23.93
23.42
26.43
25.59
25.21
24.40
23.80
23.22
21.86
21.07
21.32
20.79
21.61
21.66
21.77
21.76
21.79
22.52
22.93
Bodies Corporate
1.68
1.77
2.06
1.70
1.58
3.62
3.06
3.04
2.93
2.84
3.26
3.22
2.55
2.21
2.13
1.93
1.80
1.86
1.75
1.66
1.67
1.60
1.55
1.45
1.46
1.26
Others (incl. Retail)
No. of shareholders
22.44
36,078
21.66
42,837
22.70
45,402
23.94
55,542
23.15
52,652
22.71
61,477
21.22
67,821
20.89
71,964
20.49
74,890
23.59
78,630
22.33
78,008
21.99
75,303
21.85
74,698
21.59
74,631
21.09
75,690
19.93
74,216
19.27
71,422
19.46
70,542
19.04
71,462
19.95
71,312
19.99
68,448
20.17
70,930
20.21
73,027
20.34
73,775
21.06
73,943
21.67
73,208
Company Profile
Overview of Hikal Ltd. covering business description, industry classification, key management, financial ratios, and listed exchange details.
Hikal Limited is an India-based company, which is engaged in the manufacturing of various chemical intermediates, specialty chemicals, active pharma ingredients and contract research activities. The Pharmaceuticals segment produces active pharmaceutical ingredients. Its facilities are in Jigani, Bangalore and Panoli, Gujrat. The Crop protection segment produces pesticides and herbicides. Its facilities are in Taloja, Mahad, Maharashtra and Panoli, Gujarat. Its human health product categories include anti-convulsant, anti-emetic, anti-histaminic, anti-depressant, anti-psychotic, anti-lipemic, and hemorheologic. Its animal health product categories include anti-tick, anti-parasitic, analgesic, anabolic steroids, female sex hormone, and NSAID. Its crop protection products are used in algaecide, biocide, fungicide, herbicide, insecticide, and intermediate. It offers contract research services for synthesis, process development, and manufacturing projects.
Hikal Limited is an India-based company, which is engaged in the manufacturing of various chemical intermediates, specialty chemicals, active pharma ingredients and contract research activities. The Pharmaceuticals segment produces active pharmaceutical ingredients. Its facilities are in Jigani, Ban...
Key personnel
Mr. Kuldeep Jain
Chief Financial Officer
Mr. Ratish Jha
President - Human Resources
Mr. Vimal Kulshrestha
President - Crop Protection
Mr. Manoj Mehrotra
President - Pharmaceuticals
Mr. Anish Dilip Swadi
Senior President - Animal Health and Business Transformation